Can Opal Biosciences’ antimicrobial compound help the fight against antibiotic resistance?




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Can Opal Biosciences’ antimicrobial compound help the fight against antibiotic resistance?
Released on: December 15, 2015. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Julie Phillips, Executive Director of BioDiem, discusses the work of their subsidiary company Opal Biosciences, who are developing a small molecule anti-microbial compound for drug-resistant infections.
  • Summary
  • Transcript
  • Participants
  • Company
Julie Phillips, Executive Director of BioDiem, discusses the work of their subsidiary company Opal Biosciences, who are developing a small molecule anti-microbial compound for drug-resistant infections.
Julie Phillips, Executive Director of BioDiem, discusses the work of their subsidiary company Opal Biosciences, who are developing a small molecule anti-microbial compound for drug-resistant infections.
Ms Julie Phillips was appointed to the position of Chief Executive Officer on July 14, 2009 and was appointed a Director on May 7, 2010. She has a strong background in the biotech and pharmaceutical industry, having worked as the CEO and Director of start-up Australian biotechnology companies operating in the life sciences sector. Her technical background in clinical trials, regulatory affairs and pharmacoeconomic assessment/pricing of therapeutics was gained in multinational pharmaceutical companies with responsibility for market entry of new products in Australia and New Zealand. She was appointed Chairman of AusBiotech Ltd in October 2014, the peak biotechnology industry association in Australia.
BioDiem is an Australian biopharmaceutical company that is focused on developing and commercialising vaccines and infectious disease therapies. Our business model is to generate income from partnerships including with other vaccine and infectious disease treatment companies through existing and new licences to its LAIV vaccine and other technologies. We have an established influenza vaccine licensing business. Our revenue comes from licence fees and royalties on sales.